Laurent Sanière
Galapagos (France)(FR)
Publications by Year
Research Areas
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Axon Guidance and Neuronal Signaling, Synthesis and Catalytic Reactions, Catalytic C–H Functionalization Methods, Neonatal Respiratory Health Research
Most-Cited Works
- → Copper-Catalyzed Nitrogen Transfer Mediated by Iodosylbenzene PhIO(2001)287 cited
- → Discovery and Optimization of an Azetidine Chemical Series As a Free Fatty Acid Receptor 2 (FFA2) Antagonist: From Hit to Clinic(2014)109 cited
- → The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis(2020)78 cited
- → Ex vivo tissue perturbations coupled to single-cell RNA-seq reveal multilineage cell circuit dynamics in human lung fibrogenesis(2023)70 cited
- → RETRACTED: The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models(2019)50 cited
- → Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial(2020)43 cited
- → Iminoiodane mediated aziridination of α-allylglycine: access to a novel rigid arginine derivative and to the natural amino acid enduracididine(2004)41 cited
- → Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells(2017)35 cited
- → Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis(2021)30 cited
- → Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors(2010)25 cited